
The policy is a drug-compounding framework, not a supplement pathway, but it changes the regulatory backdrop for peptide products, drug preclusion arguments, and gray-market competition.
Companies must have a realistic understanding of the timeframes and effort involved.
For food and supplement manufacturers who are serious about pursuing and maintaining non-GMO verification, understanding the growth and trends of non-GMO production is important, as is continually tracking where and how GM production is occurring. Contamination is a legitimate threat, Heroux warns. “Choosing suppliers who grow non-GMO foods that are not in close proximity to GM crops, or who otherwise have strong traceability and segregation practices in place,” is a high priority, she says.






